Aug 13, 2025 9:25 am EDT bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
Aug 13, 2025 8:00 am EDT bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
Jul 29, 2025 8:00 am EDT Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
Jul 23, 2025 8:00 am EDT Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
Jul 22, 2025 9:00 am EDT Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
Jul 15, 2025 9:00 am EDT bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
Jul 9, 2025 9:00 am EDT Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
Jun 26, 2025 9:00 am EDT bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
Jun 24, 2025 9:00 am EDT bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
Jun 11, 2025 9:00 am EDT bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
